Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Whole-organ mapping was used to study molecular changes in the evolution of bladder cancer from field effects. We identified more than 100 dysregulated pathways, involving immunity, differentiation, and transformation, as initiators of carcinogenesis. Dysregulation of interleukins signified the involvement of inflammation in the incipient phases of the process. An aberrant methylation/expression of multiple genes signified dysregulation of the differentiation program. We identified three types of mutations based on their geographic distribution. The most common were mutations restricted to individual mucosal samples that targeted uroprogenitor cells. Two types of mutations were associated with clonal expansion and involved large areas of mucosa. The α mutations occurred at low frequencies while the β mutations increased in frequency with disease progression. Modeling revealed that bladder carcinogenesis spans 10-15 years and can be divided into dormant and progressive phases. The progressive phase lasted 1-2 years and was driven by β mutations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209726PMC
http://dx.doi.org/10.1016/j.isci.2022.104551DOI Listing

Publication Analysis

Top Keywords

bladder cancer
8
field effects
8
types mutations
8
mutations
6
origin bladder
4
cancer mucosal
4
mucosal field
4
effects whole-organ
4
whole-organ mapping
4
mapping study
4

Similar Publications

Long-term complications in patients with bladder-prostate rhabdomyosarcoma treated with brachytherapy: a systematic review.

Pediatr Surg Int

September 2025

Pediatric Surgery Unit, Department of Women's and Children's Health, University of Padua, Via Nicolò Giustiniani, 35100, Padua, Italy.

Introduction: Brachytherapy has been used for the multimodal treatment of pediatric bladder-prostate rhabdomyosarcoma in the last two decades. The aim of this systematic review is to gather the current evidence about this innovative technique with a special focus on long-term outcomes.

Methods: According to PRISMA criteria, PubMed, Scopus, and Web of Science were searched for papers published between 2000 and 2022.

View Article and Find Full Text PDF

Background: High-dose-rate (HDR) brachytherapy is essential in the treatment of locally advanced cervical cancer. While Iridium-192 (Ir-192) is commonly used, its short half-life imposes logistical and financial constraints, particularly in low- and middle-income countries (LMICs). Cobalt-60 (Co-60), with a longer half-life and lower operational costs, is a viable alternative.

View Article and Find Full Text PDF

Bladder cancer (BlCa) exhibits a highly heterogeneous molecular landscape and treatment response, underlining the pressing need for personalized prognosis. N6-methyladenosine (m6A) constitutes the most abundant RNA modification, modulates RNA biology/metabolism, and maintains cellular homeostasis, with its dysregulation involved in cancer initiation and progression. Herein, we evaluated the clinical value of METTL3 m6A methyltransferase, the main catalytic component of m6A methylation machinery, in improving BlCa patients' risk stratification and prognosis.

View Article and Find Full Text PDF

Purpose Of Review: Nonmuscle-invasive bladder cancer (NMIBC) patients with BCG-unresponsive disease have limited treatment options beyond radical cystectomy. With ongoing BCG shortages and the urgent need for bladder-preserving alternatives, this review examines the emerging role of oncolytic virus therapy as a novel intravesical treatment approach for this challenging patient population.

Recent Findings: Multiple oncolytic viral platforms have entered clinical trials for NMIBC treatment, demonstrating promising efficacy and safety profiles.

View Article and Find Full Text PDF